Unsplash+Clinical DataMoonLake’s sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s BimzelxMost inflammatory arthritis patients on MoonLake Immunotherapeutics’ sonelokimab met the response criteria, furthering the Swiss biotech’s attempt to challenge UCB for a blockbuster market. more ➔
financingSyndex Bio raises $15.5M seed and unveils mcPCR platform for DNA methylation analysisCambridge, UK-based Syndex Bio has announced on Monday the introduction of its proprietary mcPCR™ (methyl-copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) meeting in Orlando, … more ➔
Neurological disordersLario Therapeutics wins $2.4m grants to advance calcium channel drugs for Parkinson’s and PTSDEdinburgh-based Lario Therapeutics has received $2.4 million (approximately €2m) in grant funding from The Michael J. Fox Foundation and Wellcome to expand its drug discovery platform targeting voltage-gated … more ➔
adobe.stock.com - ipopbaAlzheimerJ&J stops enrollment in an AC Immune-partnered Alzheimer trial, but the reason is not yet clearA pause in the collaborative Alzheimer trial of Johnson & Johnson and partner AC Immune from Switzerland raises some questions. Whether the pause has something to do with overall recruting difficulties … more ➔
COPDForbion and Sanofi drive $75M investment in COPD biotech AltesaForbion has led a $75 million investment in Altesa BioSciences, positioning the biotech to run a phase IIb trial in chronic obstructive pulmonary disease (COPD) patients in the second quarter. more ➔
Unsplash+Drug discoveryNovartis expands cardiovascular pipeline with $1.8bn macrocycle agreement with Unnatural ProductsCalifornia-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic peptide … more ➔
NeurologyPLL Therapeutics reports positive phase I/II data for gut-targeting ALS therapyThe French biopharmaceutical company, PLL Therapeutics, announced positive results from a phase I/II clinical trial for its investigational therapy PLL001 to treat amyotrophic lateral sclerosis (ALS), … more ➔
Unsplash+OphthalmologyAxol buys Newcells’ ophthalmology business to grow drug discovery portfolioAxol Bioscience has acquired Newcells Biotech’s ophthalmology business to expand its portfolio of drug discovery and safety testing models. more ➔
BoehringerBoehringer drops inhaled gene therapy for cystic fibrosisSetback for Boehringer Ingelheim: the company has halted development of its inhaled gene therapy BI 3720931 for cystic fibrosis after a phase 1/2 trial failed to deliver efficacy data supporting further … more ➔
Bayer AGBayerUS settlement: Has Bayer untied the Monsanto knot?Years of uncertainty surrounding the numerous pending lawsuits against Bayer’s Monsanto unit could now be brought to an end through a costly but capped court settlement. Under the proposed agreement, … more ➔
Unsplash+
adobe.stock.com - ipopba
Unsplash+
Unsplash+
Bayer AG